Thursday, 15 July 2021, 4:05 pm
Adlai Nortye Ltd. (hereinafter referred to as Adlai
Nortye ), a global biopharmaceutical company focused on
developing innovative oncology drugs, today announced the
completion of $100 million Series D financing round. Co-led
by SDIC Fund Management and Tigermed, this round of
financing is participated by Legend Star, Wuxi Biologicals
Healthcare Ventures, Triwise Capital, Qingdao Mukui, Guolian
Industrial Investment, Tian Ge Interactive, etc. Proceeds
from the financing will be used to accelerate the
development of ongoing clinical and preclinical programs,
expand drug portfolio through in-house R&D capability,
in-licensing, mergers and acquisitions and other strategic
collaborations. We intend to develop differentiated
Business Scoop » Adlai Nortye Raises $100 Million In Series D Financing, Co-led By SDIC Fund Management And Tigermed
scoop.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scoop.co.nz Daily Mail and Mail on Sunday newspapers.
Chinese biopharmaceutical firm Adlai Nortye bags $100m in a Series D round
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.